Sequential release of salidroside and paeonol from a nanosphere-hydrogel system inhibits ultraviolet B-induced melanogenesis in guinea pig skin

International Journal of Nanomedicine

Volumn 9, Issue 1, 2014, Pages 1897-1908

  Peng, Li Hua ^a   Xu, Shen Yao ^a   Shan, Ying Hui ^a   Wei, Wei ^a   Liu, Shuai ^a   Zhang, Chen Zhen ^a   Wu, Jia He ^a   Liang, Wen Quan ^a   Gao, Jian Qing ^a,b  

^a ZHEJIANG UNIVERSITY   (China)

^b The Novel Transdermal Research Center of Jiangsu Province   (China)

Author keywords

Anti melanogenesis; Nanosphere; Paeonol; Salidroside; Sequential drug release

Indexed keywords

CARBOMER; CLOTRIMAZOLE; DYNASAN; GLYCEROL BEHENATE; MIGLYOL; MONOPHENOL MONOOXYGENASE; NANOSPHERE; PEONOL; PHOSPHATIDYLCHOLINE; POLYSORBATE 80; SALIDROSIDE; UNCLASSIFIED DRUG; XANTHAN; DELAYED RELEASE FORMULATION; DERMATOLOGICAL AGENT; DRUG COMBINATION; GLUCOSIDE; HERBACEOUS AGENT; HYDROGEL; MELANIN; NANOCAPSULE; PAEONAL; PHENOL DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG POTENTIATION; DRUG RELEASE; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; GUINEA PIG; HYDROGEL; IN VITRO STUDY; MELANOCYTE; MELANOGENESIS; NONHUMAN; PARTICLE SIZE; PHYSICAL PARAMETERS; POLYDISPERSITY INDEX; RADIATION EXPOSURE; SURFACE PROPERTY; SUSTAINED DRUG RELEASE; TOXICITY TESTING; ULTRAVIOLET B RADIATION; ZETA POTENTIAL; ADMINISTRATION AND DOSAGE; ANIMAL; BIOSYNTHESIS; CELL CULTURE; CELL SURVIVAL; CHEMISTRY; DELAYED RELEASE FORMULATION; DIFFUSION; DRUG COMBINATION; DRUG EFFECTS; NEOPLASMS, RADIATION-INDUCED; PHYSIOLOGY; RADIATION RESPONSE; SYNTHESIS; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME; ULTRASTRUCTURE; ULTRAVIOLET RADIATION;

ADMINISTRATION, TOPICAL; ANIMALS; CELL SURVIVAL; CELLS, CULTURED; DELAYED-ACTION PREPARATIONS; DERMATOLOGIC AGENTS; DIFFUSION; DRUG COMBINATIONS; DRUGS, CHINESE HERBAL; GLUCOSIDES; GUINEA PIGS; HYDROGELS; MELANINS; MELANOCYTES; NANOCAPSULES; NANOSPHERES; NEOPLASMS, RADIATION-INDUCED; PHENOLS; TREATMENT OUTCOME; ULTRAVIOLET RAYS;

EID: 84899154113     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S59290     Document Type: Article

References (52)

1. Costin GE, Hearing VJ. Human skin pigmentation: melanocytes modulate skin color in response to stress. FASEB J. 2007;21:976-994.
2. Yamaguchia Y, Nagasawa T, Nakamura N, et al. Successful treatment of photo-damaged skin of nano-scale atRA particles using a novel transdermal delivery. J Control Release. 2005;104:29-40.
3. Akeo K, Amaki S, Suzuki T, Hiramitsu T. Melanin granules prevent the cytotoxic effects of L-DOPA on retinal pigment epithelial cells in vitro by regulation of NO and superoxide radicals. Pigment Cell Res. 2000;13:80-88.
4. Schallreuter KU, Hordinsky MK, Wood JM. Thioredoxin reductase. Role in free radical reduction in different hypopigmentation disorders. Arch Dermatol. 1987;123:615-619.
5. Altaei T. The treatment of melasma by silymarin cream. BMC Dermatol. 2012;12:18.
6. Del BS, Bernerd F. Relationship between skin color and skin response to ultraviolet light. Int J Dermatol. 2012;Suppl 1:12-18.
7. Chen N, Hu Y, Li WH, Eisinger M, Seiberg M, Lin CB. The role of keratinocyte growth factor in melanogenesis: a possible mechanism for the initiation of solar lentigines. Exp Dermatol. 2010;19:865-872.
8. Chapman MS, Quitadamo MJ, Perry AE. Pigmented squamous cell carcinoma. J Cutan Pathol. 2000;27:93-95.
9. Li N, Peng LH, Chen X, et al. Transcutaneous vaccines: novel advances in technology and delivery for overcoming the barriers. Vaccine. 2011;29:6179-6190.
10. Stratigos AJ, Forsea AM, van der Leest RJ, et al. Euromelanoma: a dermatology-led European campaign against nonmelanoma skin cancer and cutaneous melanoma. Past, present and future. Br J Dermatol. 2012;167 Suppl 2:99-104.
11. Yanase H, Ando H, Horikawa M, Watanabe M, Mori T, Matsuda N. Possible involvement of ERK 1/2 in UVA-induced melanogenesis in cultured normal human epidermal melanocytes. Pigment Cell Res. 2001;14:103-109.
12. Abdel-Malek ZA, Kadekaro AL, Swope VB. Stepping up melanocytes to the challenge of UV exposure. Pigment Cell Res. 2010;23:171-186.
13. Solano F, Briganti S, Picardo M, et al. Hypopigmenting agents: an updated review on biological, chemical and clinical aspects. Pigment Cell Res. 2006;19:550-571.
14. Rees JL. Genetics of hair and skin color. Annu Rev Genet. 2003;37: 67-90.
15. Regad T. Molecular and cellular pathogenesis of melanoma initiation and progression. Cell Mol Life Sci. 2013;70:4055-4065.
16. Ravnbak MH, Philipsen PA, Wiegell SR, Wulf HC. Skin pigmentation kinetics after UVB exposure. Acta Derm Venereol. 2008;88:223-228.
17. Dynoodt P, Mestdagh P, Van Peer G, et al. Identification of miR-145 as a key regulator of the pigmentary process. J Invest Dermatol. 2013;133:201-209.
18. Peng H, Liu S, Xu SY, et al. Inhibitory effects of salidroside and paeonol on tyrosinase activity and melanin synthesis in mouse B16F10 melanoma cells and ultraviolet B-induced pigmentation in guinea pig skin. Phytomedicine. 2013;20:1082-1087.
19. Shi J, Ma F, Wang X, et al. Formulation of liposome gels of paeonol for transdermal drug delivery by Box-Behnken statistical design. J Liposome Res. 2012;22:270-278.
20. Luo, Shen Q, Chen J. Transdermal delivery of paeonol using cubic gel and microemulsion gel. Int J Nanomedicine. 2011;6:1603-1610.
21. Peng H, Dong R, Wang S, et al. A pH-responsive nano-carrier with mesoporous silica nanoparticles cores and poly(acrylic acid) shell-layers: fabrication, characterization and properties for controlled release of salidroside. Int J Pharm. 2013;446:153-159.
22. Verma P, Pathak K. Nanosized ethanolic vesicles loaded with econazole nitrate for the treatment of deep fungal infections through topical gel formulation. Nanomedicine. 2012;8:489-496.
23. de Paula E, Cereda CM, Fraceto LF, et al. Micro and nanosystems for delivering local anesthetics. Expert Opin Drug Deliv. 2012;9: 1505-1524.
24. Basnet P, Škalko-Basnet N. Nanodelivery systems for improved topical antimicrobial therapy. Curr Pharm Des. 2013;19:7237-7243.
25. Peng H, Wei W, Qi XT, et al. Epidermal stem cells manipulated by pDNA-VEGF165/CYD-PEI nanoparticles loaded gelatin/β-TCP matrix as therapeutic agent and gene delivery vehicle for wound healing. Mol Pharm. 2013;10:3090-3102.
26. Friedman AJ, Phan J, Schairer DO, et al. Antimicrobial and anti-inflammatory activity of chitosan-alginate nanoparticles: a targeted therapy for cutaneous pathogens. J Invest Dermatol. 2013;133:1231-1239.
27. Chen X, Peng LH, Shan YH, et al. Astragaloside IV-loaded nanoparticle-enriched hydrogel induces wound healing and anti-scar activity through topical delivery. Int J Pharm. 2013;447:171-181.
28. Hadinoto K, Sundaresan A, Cheow WS. Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review. Eur J Pharm Biopharm. 2013;85(3 Pt A):427-443.
29. Yang H, Tyagi P, Kadam RS, et al. Hybrid dendrimer hydrogel/PLGA nanoparticle platform sustains drug delivery for one week and antiglaucoma effects for four days following one-time topical administration. ACS Nano. 2012;6:7595-7606.
30. Pradhan, Singh D, Singh MR. Novel colloidal carriers for psoriasis: current issues, mechanistic insight and novel delivery approaches. J Control Release. 2013;170:380-395.
31. Fan X, Chen J, Shen Q. Docetaxel-nicotinamide complex-loaded nanostructured lipid carriers for transdermal delivery. Int J Pharm. 2013;458:296-304.
32. Nishizaka T, Nomura T, Sano T, Higuchi K, Nagatomo F, Ishihara A. Hyperbaric oxygen improves ultraviolet B irradiation-induced melanin pigmentation and diminishes senile spot size. Skin Res Technol. 2011;17(3):332-338.
33. Stout GJ, Blasco MA. Telomere length and telomerase activity impact the UV sensitivity syndrome xeroderma pigmentosum C. Cancer Res. 2013;73:1844-1854.
34. Hoshino T, Matsuda M, Yamashita Y, et al. Suppression of melanin production by expression of HSP70. J Biol Chem. 2010;285: 13254-13263.
35. Kim JH, Min KH, Heo CY, et al. Histological evaluation of dermal tissue remodeling with the 1444-nm neodymium:yttrium-aluminum-garnet laser in in vivo model. J Dermatol. 2013;40:706-710.
36. Kabashima K, Sakabe JI, Yoshiki R, Tabata Y, Kohno K, Tokura Y. Involvement of Wnt signaling in dermal fibroblasts. Am J Pathol. 2010;176:721-732.
37. Bao YP, An W, Turner CH, et al. The critical role of surfactants in the growth of cobalt nanoparticles. Langmuir. 2010;26:478-483.
38. Curto EV, Kwong C, Hermersdörfer H, et al. Inhibitors of mammalian melanocyte tyrosinase: in vitro comparisons of alkyl esters of gentisic acid with other putative inhibitors. Biochem Pharmacol. 1999;57:663-672.
39. Burnett CL, Bergfeld WF, Belsito DV, et al. Final report of the safety assessment of kojic acid as used in cosmetics. Int J Toxicol. 2010;29(Suppl 6):244S-273S.
40. Chang TS. An updated review of tyrosinase inhibitors. Int J Mol Sci. 2009;10:2440-2475.
41. Pieroni A, Quave CL, Villanelli ML, et al. Ethnopharmacognostic survey on the natural ingredients in folk cosmetics, cosmeceuticals and remedies skin disease in the inland Marches, Central-Eastern Italy. J Ethnopharmacol. 2004;91:331-344.
42. Momtaz S, Mapunya BM, Houghton PJ, et al. Tyrosinase inhibition by extracts and constituents of Sideroxylon inerme L. stem bark, used in South Africa for skin lightening. J Ethnopharmacol. 2008;119:507-512.
43. Jang JY, Lee JH, Jeong SY, Chung KT, Choi YH, Choi BT. Partially purified Curcuma longa inhibits alpha-melanocyte-stimulating hormone-stimulated melanogenesis through extracellular signal-regulated kinase or Akt activation-mediated signalling in B16F10 cells. Exp Dermatol. 2009;18:689-694.
44. Bao MH, Zhang YW, Zhou HH. Paeonol suppresses oxidized low-density lipoprotein induced endothelial cell apoptosis via activation of LOX-1/p38MAPK/NF-κB pathway. J Ethnopharmacol. 2013;146:543-551.
45. Li H, Wang S, Zhang B, et al. Influence of co-administered danshensu on pharmacokinetic fate and tissue distribution of paeonol in rats. Planta Med. 2012;78:135-140.
46. Zhu J, Wan X, Zhu Y, Ma X, Zheng Y, Zhang T. Evaluation of salidroside in vitro and in vivo genotoxicity. Drug Chem Toxicol. 2010;33: 220-226.
47. Zhang H, Shen WS, Gao CH, Deng LC, Shen D. Protective effects of salidroside on epirubicin-induced early left ventricular regional systolic dysfunction in patients with breast cancer. Drugs R D. 2012;12: 101-106.
48. Wang XL, Wang X, Xiong LL, et al. Salidroside improves doxorubicin-induced cardiac dysfunction by suppression of excessive oxidative stress and cardiomyocyte apoptosis. J Cardiovasc Pharmacol. 2013;62: 512-523.
49. Li D, Fu Y, Zhang W, et al. Salidroside attenuates inflammatory responses by suppressing nuclear factor-κB and mitogen activated protein kinases activation in lipopolysaccharide-induced mastitis in mice. Inflamm Res. 2013;62:9-15.
50. Zhang WL, Gu X, Bai H, Yang RH, Dong CD, Liu JP. Nanostructured lipid carriers constituted from high-density lipoprotein components for delivery of a lipophilic cardiovascular drug. Int J Pharm. 2010;391:313-321.
51. Bhaskar K, Mohan CK, Lingam M, Mohan SJ, Venkateswarlu V, Rao YM. Development of SLN and NLC enriched hydrogels for transdermal delivery of nitrendipine: in vitro and in vivo characteristics. Drug Dev Ind Pharm. 2009;35:98-113.
52. Yu JS, Kim AK. Effect of combination of taurine and azelaic acid on antimelanogenesis in murine melanoma cells. J Biomed Sci. 2010;17 Suppl 1:S45-S49.